109 related articles for article (PubMed ID: 38855496)
1. Prognostic Value of Liver Biomarkers in Hepatocellular Carcinoma Patients Undergoing Yttrium 90 Transarterial Radioembolization (TARE): A Retrospective Pilot Study.
Bayona Molano MDP; Kolber M; Barrera JV; Akram MR; Alnablsi MW; Pothini T; Salem R; Singal AG
Cureus; 2024 Jun; 16(6):e61904. PubMed ID: 38855496
[TBL] [Abstract][Full Text] [Related]
2. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization.
Lewandowski RJ; Kulik LM; Riaz A; Senthilnathan S; Mulcahy MF; Ryu RK; Ibrahim SM; Sato KT; Baker T; Miller FH; Omary R; Abecassis M; Salem R
Am J Transplant; 2009 Aug; 9(8):1920-8. PubMed ID: 19552767
[TBL] [Abstract][Full Text] [Related]
3. Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study.
Kolligs F; Arnold D; Golfieri R; Pech M; Peynircioglu B; Pfammatter T; Ronot M; Sangro B; Schaefer N; Maleux G; Munneke G; Pereira H; Zeka B; de Jong N; Helmberger T;
JHEP Rep; 2023 Feb; 5(2):100633. PubMed ID: 36593888
[TBL] [Abstract][Full Text] [Related]
4. Prognostic ability of inflammation-based markers in radioembolization for hepatocellular carcinoma.
Yoneoka G; Bozhilov K; Wong LL
Hepatoma Res; 2020; 6():. PubMed ID: 33134551
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Liver Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma After Segmental Transarterial Radioembolization.
Hardy-Abeloos C; Lazarev S; Ru M; Kim E; Fischman A; Moshier E; Rosenzweig K; Buckstein M
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):968-976. PubMed ID: 31536781
[TBL] [Abstract][Full Text] [Related]
6. Comparison of health-related quality of life after transarterial chemoembolization and transarterial radioembolization in patients with unresectable hepatocellular carcinoma.
Kirchner T; Marquardt S; Werncke T; Kirstein MM; Brunkhorst T; Wacker F; Vogel A; Rodt T
Abdom Radiol (NY); 2019 Apr; 44(4):1554-1561. PubMed ID: 30311050
[TBL] [Abstract][Full Text] [Related]
7. Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis.
Patel MV; Davies H; Williams AO; Bromilow T; Baker H; Mealing S; Holmes H; Anderson N; Ahmed O
J Med Econ; 2023; 26(1):1061-1071. PubMed ID: 37632520
[TBL] [Abstract][Full Text] [Related]
8. Boosted-Dose Yttrium-90 Radiation Segmentectomy or Lobectomy for Hepatocellular Carcinoma Refractory to Prior Transarterial Embolization or Chemoembolization: A Single Institution Retrospective Case Series.
Srinivas S; Rose SC; Al Jammal O; Hsieh LJ; Rockwell HD; Duncan DP; Minocha J; Berman ZT
Cardiovasc Intervent Radiol; 2023 Apr; 46(4):460-469. PubMed ID: 36854903
[TBL] [Abstract][Full Text] [Related]
9. Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma.
Kallini JR; Gabr A; Salem R; Lewandowski RJ
Adv Ther; 2016 May; 33(5):699-714. PubMed ID: 27039186
[TBL] [Abstract][Full Text] [Related]
10. Hepatic decompensation after transarterial radioembolization: A retrospective analysis of risk factors and outcome in patients with hepatocellular carcinoma.
Reincke M; Schultheiss M; Doppler M; Verloh N; Uller W; Sturm L; Thimme R; Goetz C; Bettinger D
Hepatol Commun; 2022 Nov; 6(11):3223-3233. PubMed ID: 36064940
[TBL] [Abstract][Full Text] [Related]
11. Survival analysis of transarterial radioembolization with yttrium-90 for hepatocellular carcinoma patients with HBV infection.
She WH; Cheung TT; Yau TC; Chan AC; Chok KS; Chu FS; Liu RK; Poon RT; Chan SC; Fan ST; Lo CM
Hepatobiliary Surg Nutr; 2014 Aug; 3(4):185-93. PubMed ID: 25202695
[TBL] [Abstract][Full Text] [Related]
12. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.
Spreafico C; Sposito C; Vaiani M; Cascella T; Bhoori S; Morosi C; Lanocita R; Romito R; Chiesa C; Maccauro M; Marchianò A; Mazzaferro V
J Hepatol; 2018 Apr; 68(4):724-732. PubMed ID: 29331342
[TBL] [Abstract][Full Text] [Related]
13. For Hepatocellular Carcinoma Treated with Yttrium-90 Microspheres, Dose Volumetrics on Post-Treatment Bremsstrahlung SPECT/CT Predict Clinical Outcomes.
Taswell CS; Studenski M; Pennix T; Stover B; Georgiou M; Venkat S; Jones P; Zikria J; Thornton L; Yechieli R; Mohan P; Portelance L; Spieler B
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765603
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study.
Kwon JH; Kim GM; Han K; Won JY; Kim MD; Lee DY; Lee J; Choi W; Kim YS; Kim DY; Han KH
Cardiovasc Intervent Radiol; 2018 Mar; 41(3):459-465. PubMed ID: 29067511
[TBL] [Abstract][Full Text] [Related]
15. Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib.
Teyateeti A; Mahvash A; Long J; Abdelsalam M; Avritscher R; Kaseb A; Odisio B; Ravizzini G; Surasi D; Teyateeti A; Macapinlac H; Kappadath SC
World J Gastroenterol; 2021 Dec; 27(47):8166-8181. PubMed ID: 35068861
[TBL] [Abstract][Full Text] [Related]
16. Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments.
Cappelli A; Pettinato C; Golfieri R
J Hepatocell Carcinoma; 2014; 1():163-82. PubMed ID: 27508185
[TBL] [Abstract][Full Text] [Related]
17. The position of transarterial chemoembolization with drug-eluting beads and yttrium-90 transarterial radioembolization in patients with hepatocellular carcinoma: Consensus statements from a Delphi-method expert panel in Turkey.
Akarca US; Akhan O; Bilgiç S; Bozkurt MF; Cantaşdemir M; Çermik TF; Çakaloğlu Y; Er Ö; Ilgıt E; Çapa Kaya G; Küçük NÖ; Numan F; Parıldar M; Türkmen C
Diagn Interv Radiol; 2021 Nov; 27(6):732-739. PubMed ID: 34792027
[TBL] [Abstract][Full Text] [Related]
18. Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality.
Kim DY; Han KH
Hepatol Int; 2016 Nov; 10(6):883-892. PubMed ID: 27126821
[TBL] [Abstract][Full Text] [Related]
19. Histogram Analysis of CT Perfusion of Hepatocellular Carcinoma for Predicting Response to Transarterial Radioembolization: Value of Tumor Heterogeneity Assessment.
Reiner CS; Gordic S; Puippe G; Morsbach F; Wurnig M; Schaefer N; Veit-Haibach P; Pfammatter T; Alkadhi H
Cardiovasc Intervent Radiol; 2016 Mar; 39(3):400-8. PubMed ID: 26216725
[TBL] [Abstract][Full Text] [Related]
20. Bilobar Radioembolization Carries the Risk of Radioembolization-Induced Liver Disease in the Treatment of Advanced Hepatocellular Carcinoma: Safety and Efficacy Comparison to Systemic Therapy with Atezolizumab/Bevacizumab.
Jeschke M; Ludwig JM; Leyh C; Pabst KM; Weber M; Theysohn JM; Lange CM; Herrmann K; Schmidt HH; Jochheim LS
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
